Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura Pharmaceuticals has announced that clinical evaluation is now allowed under an active investigational new drug application for a second undisclosed opioid analgesic product candidate using Aversion technology.
Subscribe to our email newsletter
This product candidate was previously licensed by Acura to King Pharmaceuticals Research and Development, a wholly owned subsidiary of King Pharmaceuticals as a result of the license, development and commercialization agreement between the companies.
Acura and King are jointly developing opioid analgesic product candidates utilizing Acura’s proprietary Aversion technology. These product candidates are intended to deter common methods of prescription drug misuse and abuse.